1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Q32 Bio Inc.

Q32 Bio Inc.

QTTB
Q32 Bio Inc.US flagNASDAQ Global Market
15.41
USD
+0.37
- -
196.88MMarket Cap

Total Valuation

Q32 Bio Inc. carries a market capitalization of 196.88M, placing it among publicly traded companies globally. Its enterprise value stands at 45.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap196.88M
Enterprise Value45.36M

Share Statistics

Q32 Bio Inc. currently has 14.63M shares outstanding.

Shares Outstanding14.63M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Q32 Bio Inc. trades at a trailing price-to-earnings ratio of 2.48. The price-to-sales ratio is 1.53, and the price-to-book ratio stands at -0.39.

PE Ratio2.48
PS Ratio1.53
PB Ratio-0.39
P/TBV Ratio1.78
P/FCF Ratio-3.01
P/OCF Ratio-3.01

Enterprise Valuation

The EV/Sales ratio of 0.84 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.12 provides insight into valuation relative to core operating earnings.

EV / Sales0.84
EV / EBITDA2.08
EV / EBIT2.12
EV / FCFN/A

Financial Position

Q32 Bio Inc. maintains a current ratio of 5.36, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.46, indicating elevated leverage, while an interest coverage ratio of 27.21 demonstrates strong ability to service its debt obligations.

Current Ratio5.36
Quick Ratio5.26
Debt / Equity29.46
Debt / EBITDA0.63
Interest Coverage27.21

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)46.58
Return on Invested Capital (ROIC)57.29
Return on Capital Employed (ROCE)-15.98
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Q32 Bio Inc.'s stock has gained approximately 606.88073% over the past 52 weeks. The 50-day moving average sits at 11.50, while the 200-day moving average is 5.96.

Beta (5Y)N/A
52-Week Price Change606.88073%
50-Day Moving Average11.50
200-Day Moving Average5.96
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Q32 Bio Inc. generated 53.74M in revenue and converted that into 33.24M in net income, yielding earnings per share of 2.59. EBITDA reached 21.77M, while operating income came in at 21.41M.

Revenue53.74M
Gross ProfitN/A
Operating Income21.41M
Pretax Income33.24M
Net Income33.24M
EBITDA21.77M
EBIT21.41M
Earnings Per Share (EPS)2.59

Balance Sheet

Q32 Bio Inc. holds 50.75M in cash and equivalents against 13.65M in total debt, resulting in a net debt position of -42.57M. Total book value stands at -212.60M, with working capital of 46.53M providing operational flexibility.

Cash & Cash Equivalents50.75M
Total Debt13.65M
Net Debt-42.57M
Equity (Book Value)-212.60M
Book Value Per Share-16.55
Working Capital46.53M

Cash Flow

Q32 Bio Inc. produced -27.40M in operating cash flow over the past twelve months.

Operating Cash Flow-27.40M
Capital ExpendituresN/A
Free Cash Flow-27.40M
FCF Per Share-2.13

Margins

Q32 Bio Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 39.84 and net profit margin of 61.86 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin39.84
Pretax Margin61.86
Profit Margin61.86
EBITDA Margin40.51

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-6.88
FCF Yield-33.23

Stock Splits

Q32 Bio Inc.'s most recent stock split took place on March 26, 2024 with a 18:1 split ratio.

Last Split Date3/26/2024
Split Ratio18:1

Scores

Q32 Bio Inc. posts an Altman Z-Score of 1.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.01